STOCK TITAN

Nkarta (NASDAQ: NKTX) launches $100M at-the-market stock sale plan

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Nkarta, Inc. entered into a Sales Agreement with Stifel, Nicolaus & Company for an at-the-market stock offering program. The company may sell, at its discretion, shares of common stock having an aggregate offering price of up to $100,000,000 through Stifel as sales agent.

The company will set sale parameters such as size, timing, daily limits and minimum prices, and will pay Stifel a commission of up to 3% of gross proceeds on shares sold. The shares will be issued under Nkarta’s effective Form S-3 registration statement and related at-the-market prospectus supplement filed with the SEC on March 25, 2026.

Positive

  • None.

Negative

  • None.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
0001787400false00017874002026-03-252026-03-25

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 25, 2026

Nkarta, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware

001-39370

47-4515206

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

1150 Veterans Boulevard

South San Francisco, CA

94080

(Address of Principal Executive Offices)

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (925) 407-1049

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

 

NKTX

 

 

Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 


 

Item 8.01 Other Events.

On March 25, 2026, Nkarta, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Stifel, Nicolaus & Company, Incorporated (“Stifel”) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $100,000,000 (the “Shares”) through Stifel as its “sales agent” (the “Agent”).

Under the Sales Agreement, the Company will set the parameters for the sale of Shares, including the number of Shares to be issued, the time period during which sales are requested to be made, limitations on the number of Shares that may be sold in any one trading day and any minimum price below which sales may not be made. Subject to the terms of the Sales Agreement, the Agent may sell the Shares by any method that is deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act, including without limitation sales made on or through the Nasdaq Global Select Market or on any other trading market for the Common Stock, in the over-the-counter market, in privately negotiated transactions or through a combination of any such methods of sale permitted by law.

The Company will pay the Agent a commission equal to up to 3% of the gross sales proceeds of any Shares sold through the Agent under the Sales Agreement, and has provided the Agent with customary indemnification and contribution rights.

The Sales Agreement will terminate upon the earlier of (i) the sale of all Shares subject to the Sales Agreement or (ii) termination of the Sales Agreement in accordance with the terms and conditions set forth therein.

Any Shares to be offered and sold under the Sales Agreement will be issued and sold pursuant to the Company’s Registration Statement on Form S-3 (File No. 333-294611), which was filed with the Securities and Exchange Commission (“SEC”) on March 25, 2026, and included an “at-the-market offering” prospectus supplement relating to the offer and sale of the Shares filed with the SEC on March 25, 2026.

The foregoing description of the Sales Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Sales Agreement, a copy of which is attached as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

O’Melveny & Myers LLP, counsel to the Company, has issued an opinion to the Company, dated March 25, 2026, relating to the validity of the Shares to be issued and sold pursuant to the Sales Agreement, a copy of which is filed as Exhibit 5.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit

Number

Description

 

 

1.1#

 

Sales Agreement (incorporated by reference to Exhibit 1.2 to Nkarta, Inc.’s Registration Statement on Form S-3 (No. 333-294611) filed with the SEC on March 25, 2026)

5.1

Opinion of O’Melveny & Myers LLP (incorporated by reference to Exhibit 5.2 to Nkarta, Inc.’s Registration Statement on Form S-3 (No. 333-294611) filed with the SEC on March 25, 2026)

23.1

 

Consent of O’Melveny & Myers LLP (contained in Exhibit 5.1)

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document).

# Certain personally identifiable information of this exhibit has been omitted pursuant to Item 601(a)(6) of Regulation S-K

 

1


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Nkarta, Inc.

Date: March 25, 2026

By:

/s/ Nadir Mahmood

Nadir Mahmood

President

 

2


FAQ

What did Nkarta (NKTX) announce in this 8-K filing?

Nkarta announced a new at-the-market offering program allowing it to sell up to $100,000,000 of common stock through Stifel. The company controls timing, size, and pricing parameters for these discretionary issuances under an effective shelf registration statement and prospectus supplement.

How large is Nkarta’s new at-the-market equity program?

The program authorizes sales of Nkarta common stock with an aggregate offering price of up to $100,000,000. Shares sold under this arrangement will be issued from the company’s Form S-3 shelf registration and the related at-the-market prospectus supplement filed on March 25, 2026.

Who is acting as sales agent for Nkarta’s at-the-market offering?

Stifel, Nicolaus & Company, Incorporated will act as sales agent for Nkarta’s at-the-market offering. Stifel may sell shares on Nasdaq, other trading markets, over-the-counter, in privately negotiated deals, or using combinations of these methods permitted by law under Rule 415(a)(4).

What commission will Nkarta pay on shares sold under this program?

Nkarta will pay Stifel a commission of up to 3% of the gross sales proceeds for any shares sold through the at-the-market program. The company has also granted Stifel customary indemnification and contribution rights in connection with acting as sales agent.

Under what registration statement will Nkarta’s ATM shares be issued?

Shares sold in the at-the-market program will be issued under Nkarta’s Registration Statement on Form S-3, File No. 333-294611. An at-the-market offering prospectus supplement covering these shares was filed with the SEC on March 25, 2026, supporting future issuances.

When does Nkarta’s at-the-market Sales Agreement terminate?

The Sales Agreement will end when all authorized shares under the $100,000,000 at-the-market program are sold or if the agreement is terminated earlier according to its terms. Termination can therefore occur either by full usage of capacity or by contractual termination provisions.

Filing Exhibits & Attachments

1 document
Nkarta, Inc.

NASDAQ:NKTX

View NKTX Stock Overview

NKTX Rankings

NKTX Latest News

NKTX Latest SEC Filings

NKTX Stock Data

150.42M
67.34M
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO